T cell lymphomas | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘T cell lymphomas’

Infinity and AbbVie partner to develop and commercialise Duvelisib for cancer… for the treatment of chronic lymphocytic leukemia

Posted in Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Enzymes and isoenzymes, Kinase, Translational Science, tagged B-cell chronic lymphocytic leukemia, Cancer - General, Chemotherapy, Clinical trial, CLL, duvelisib, gene expression, isoforms, medicinal chemistry, Non-Hodgkin lymphoma, PI3 kinase, PI3K/AKT pathway, T cell lymphomas on November 8, 2014| Leave a Comment »

Infinity and AbbVie partner to develop and commercialise Duvelisib for cancer… for the treatment of chronic lymphocytic leukemia

Reporter: Stephen J. Williams, PhD

Duvelisib is a dual phosphoinositide-3-kinase (PI3K) delta and PI3K gamma inhibitor. The delta and gamma isozymes are selectively expressed in leukocytes. This article (at Dr. Melvin Crasto’s blog newdrugapprovals.org) discusses the synthesis of Duvelisib and mentions additional clinical trials underway including a phase II trial for the treatment of patients with mild asthma undergoing allergen challenge, for the treatment of rheumatoid arthritis and for the treatment of refractory indolent non-Hodgkin’s lymphoma. Phase I clinical trials for the treatment of advanced hematological malignancies (including T-cell lymphoma and mantle cell lymphoma). The drug was originally developed at Takeda subsidiary Intellikine.

SOURCE

http://newdrugapprovals.org/2014/09/09/infinity-and-abbvie-partner-to-develop-and-commercialise-duvelisib-for-cancer-for-the-treatment-of-chronic-lymphocytic-leukemia/